What is it about?
This review focuses on the extended duration of standard tuberculosis (TB) therapy which suggests the inefficiency of current first-line TB drugs to eliminate the causative agent Mycobacterium tuberculosis (Mtb). Among multiple potential causes, the review highlights the poor distribution of TB drugs into the pulmonary lesions in which the bacilli reside and suggests ways in which the target site could be studied to aid in better drug development.
Featured Image
Why is it important?
The review shows that drug permeation and efficacy at the target site of pulmonary tuberculosis (TB) are potential drivers for anti-TB efficacy and that a paradigm shift away from plasma concentrations at the target site offers the potential for the development of more efficacious compounds.
Perspectives
Writing this article with esteemed members of my University was a great privilege and was extremely enjoyable. I hope that the article highlights the need for greater understanding of what is driving anti-TB efficacy at the target site of TB pathology.
Lloyd Tanner
University of Cape Town
Read the Original
This page is a summary of: Drug permeation and metabolism in Mycobacterium tuberculosis
: Prioritising local exposure as essential criterion in new TB drug development, IUBMB Life, June 2018, Wiley,
DOI: 10.1002/iub.1866.
You can read the full text:
Contributors
The following have contributed to this page
